65,437 trials
Spinal Cord Injury · Neurogenic Bladder · Urinary Tract Infection
Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…
Severe Crohn's Disease · Anxiety
Primary: Change in State Trait Anxiety Index (STAI) State Scores From Baseline to After 6 Months of Treatment With Adalimumab — -1.7 scores on a scale
Oral Hygiene
Primary: Modified Lobene Stain Index (MLSI) at Week 6 — 0.97; 1.22 Score on a Scale — p=0.1313
Purpura, Thrombocytopaenic, Idiopathic
Primary: Percentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of…
Head and Neck Cancer
Primary: Rate of Movement of Normal Tissue
Dysphagia
Primary: Change in Penetration-Aspiration Scale (PAS) Score — 0.01; -0.57 Change in points on PAS
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c to Week 12 — -0.42; -0.52; -0.92; -0.80 % change
Male Breast Cancer · Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Maximum Tolerated Dose Determined by Dose-limiting Toxicities — 0; 0 Patients experiencing DLT
Fever Without Source
Primary: Antibiotic Prescription Rate — 54; 59 participants — p=1
Prevention of the Meningococcal Disease
Primary: Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule — 1.18; 53; 2.27; 143 Titers
Head or Neck Cancer
Primary: Overall Response Rate — 2; 5 Participants
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using the Cockcroft-Gault (CG) Equation at Week 24 (Cohort 1) — 72.9; -5.2 mL/min
Precancerous Condition · Stage 0 Melanoma · Stage I Melanoma
Primary: Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 1's Evaluation — 0.50; -0.12 score
Schizophrenia
Primary: Composite MATRICS Consensus Cognitive Battery Score — 27.9; 31.3; 32.5 composite score — p=0.21
Acute Leukemia · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia
Primary: Relapse at 2 Years Post-transplant. — 6; 4 participants